Structure Therapeutics Inc. Receives 88.43 Consensus PT from Brokerages
| PRRUF Stock | USD 0.20 0.00 0.00% |
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
Immutep |
Shares of Structure Therapeutics Inc. have received a consensus rating of Buy from the seven analysts that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the
Read at thelincolnianonline.com
 |
Immutep Fundamental Analysis
We analyze Immutep's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Immutep is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Immutep Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immutep pink sheet to make a market-neutral strategy. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics with similar companies.
Peers
Immutep Related Equities
| IMMX | Immix Biopharma | 5.48 | ||||
| CRNX | Crinetics Pharmaceuticals | 5.21 | ||||
| DSGN | Design Therapeutics | 4.23 | ||||
| APLT | Applied Therapeutics | 2.48 | ||||
| AADI | Aadi Bioscience | 1.67 | ||||
| CYTK | Cytokinetics | 0.30 | ||||
| CGEM | Cullinan Oncology | 0.24 | ||||
| ALVR | Allovir | 0.73 | ||||
| GPCR | Structure Therapeutics | 1.30 | ||||
| CDTX | Cidara Therapeutics | 1.58 | ||||
| VRDN | Viridian Therapeutics | 1.96 | ||||
| ENVB | Enveric Biosciences | 2.47 | ||||
| ZNTL | Zentalis Pharmaceuticals | 3.05 | ||||
| CTMX | CytomX Therapeutics | 3.31 | ||||
| ALXO | Alx Oncology | 3.80 | ||||
| ELEV | Elevation Oncology | 4.00 | ||||
| SANA | Sana Biotechnology | 5.65 | ||||
| ZURA | Zura Bio | 9.71 | ||||
| OLMA | Olema Pharmaceuticals | 12.76 | ||||
| SLN | Silence Therapeutics | 12.84 | ||||
| ADCT | ADC Therapeutics | 36.21 |
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |